Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jul 28, 2015
Eisai Inc. announced today the U.S. Food and Drug Administration (FDA) granted lenvatinib, the company's multiple receptor tyrosine kinase inhibitor, Breakthrough Therapy designation for the...
- Jul 16, 2015Deal Supports Strategic Directions of Both Companies and Expands Collaboration
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it has entered into a definitive agreement to transfer ownership of its Research Triangle Park (RTP)...
-
Jun 22, 2015New Indication Provides a Treatment Option for Epilepsy Patients Who Suffer from PGTC Seizures that are not Adequately Controlled with Current Treatment
Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA® (perampanel) CIII for adjunctive therapy in the treatment of primary generalized tonic-clonic...
- Jun 1, 2015
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Ivor Macleod to the position of Senior Vice President, Chief Financial Officer (CFO)...
-
Jun 1, 2015Lenvatinib, investigated in patients with metastatic renal cancer, showed an increase in progression-free survival (PFS)
Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival...
